Herborium Group, Inc. (HBRM) Commences the Sale of AcnEase(R), Its Proprietary, Novel, Herbal Acne Treatment in Germany, the Lar
May 28 2009 - 3:00PM
Marketwired
Herborium Group, Inc. (PINKSHEETS: HBRM), a botanical therapeutics�
company that develops, licenses and markets novel botanical
ingredients-based medicinal products, announced today that it has
entered the German market with its proprietary AcnEase� medicine
for the treatment of Acne and Rosacea. AcnEase represents,
possibly, one of the most important product introductions into the
field of Acne treatment in the last several decades since it is the
only 100% systemic, all-herbal medicine that demonstrated success
rates of approximately 95% in clinical studies. The German market
is the largest in Europe for natural-based medicinal products (over
$30 billion) and is also a very large market for Dermatologics, in
particular acne products, with expected sales of over $3 billion in
2013.
"In recent years, the level of innovation in the area of
dermatologic acne treatment has dwindled. This has caused an
erosion of the market share of several leading players. As major
brands continue to lose ground to smaller, specialized players,
opportunities are being created for companies like Herborium that
can provide novel medicinal alternatives and implement effective
lifecycle management, thereby accessing lucrative revenues," notes
Dr. Agnes P. Olszewski, CEO of Herborium. "With our presence in the
UK and now in Germany, in addition to our strong presence in the US
market, Herborium is certainly going to take advantage of these
opportunities," adds Dr. Olszewski.
For more information about Herborium and AcnEase visit the
following links: www.herborium.com and www.acnease.com
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics� company, is
focused on developing, licensing, and marketing proprietary,
botanical-based medicinal products to consumers and healthcare
professionals. The Company business model focuses on emerging
market opportunities spearheaded by the growth of a new market
sector located between high-cost, high-risk, ethical
pharmaceuticals and commoditized classic nutraceuticals
(supplements). The Company uses clinical validation and a proactive
regulatory strategy based on the FDA Guidance for Industry:
Botanical Drug Products (FDA Guidance 2004) to establish and
maintain a differential advantage. Herborium harvests its
therapeutic candidates from Traditional Chinese Medicine and
utilizes Western regulatory, clinical and marketing strategies to
successfully introduce the products to Western markets. The company
has secured a pipeline of botanical ingredients-based products in
the areas of dermatological needs, Prostate Health (BPH), Liver
Diseases, Women's Health and selected sexual disorders resulting
from cardiovascular disease, use of anti-depressants, surgical
procedures, and other problems. Herborium Group sells its products
in the United States, the United Kingdom, and continental Europe
through a network of distributors, specialty retailers, and
e-commerce.
Safe Harbor Statement: This release contains forward-looking
statements with respect to the results of operations and business
of Sunrise Consulting Group, Inc., which involves risks and
uncertainties. The Company's actual future results could materially
differ from those discussed. The Company intends that such
statements about the Company's future expectations, including
future revenues and earnings, and all other forward-looking
statements be subject to the "Safe Harbors" provision of the
Private Securities Litigation Reform Act of 1995.
Contact: Herborium Group, Inc. Dr. Agnes Olszewski CEO 201 647
3757
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jul 2023 to Jul 2024